EGFR and non-small cell lung carcinoma: Owing to the promising outcomes shown in the AURA serial studies, osimertinib was the first third-generation EGFR-TKI to be clinically approved for treating patients with NSCLC harboring the EGFR T790M mutation (4, 6).